The FDA on April 13, 2021, granted accelerated approval to TRODELVY® for patients with locally advanced or metastatic Urothelial Cancer (mUC) who previously received a Platinum-containing chemotherapy and either a Programmed Death receptor-1 (PD-1) or a Programmed Death-Ligand 1 (PD-L1) inhibitor. TRODELVY® is a product of Immunomedics Inc.
Bottom Ad
Advertisement
Subscribe
